NICE has approved 18 of the 24 medications the agency has been asked to review for cost effectiveness on the Cancer Drugs Funds list, without disqualifying any. NICE is charged with determining if drugs qualify for purchasing support from the UK’s National Health Service.
The Cancer Drugs Fund was established by the UK government in 2010 to help patients pay for cancer drugs that were not widely available through the NHS. But the fund quickly exceeded its £200 million ($260 million) budget, NICE said.
In 2016, NICE was directed to conduct cost-effectiveness appraisals for the drugs on the CDF list, plus any newly licensed cancer drugs.